

Exhibit 99.1

Translation for information purpose only

INVENTIVA

Société Anonyme with a Board of Directors
with a share capital of EUR 956,623.91
Registered Office: 50, Rue de Dijon, 21121 Daix
537 530 255 Trade and Companies Register of Dijon

Notice of meeting

The shareholders of INVENTIVA (the “**Company**”) are informed that the ordinary and extraordinary general meeting (the “**General Meeting**”) will be held on **May 22, 2025 at 9 a.m.**, at: Hôtel Villa M, 24-30, boulevard Pasteur - 75015 Paris, France.

As a reminder, the agenda of the General Meeting, unchanged from that published in the notice of the General Meeting published in the *Bulletin des Annonces Légales Obligatoires* on April 11, 2025 (bulletin n°44), is as follows:

Agenda

Reading of the reports of the Board of Directors and the Statutory Auditors;

Ordinary items

1. Approval of the statutory financial statements for the financial year ended December 31, 2024;
2. Approval of the consolidated financial statements for the financial year ended December 31, 2024;
3. Appropriation of profit/loss for the financial year ended December 31, 2024;
4. Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
5. Approval of the subscription agreement for royalty certificates issued by the Company signed on July 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
6. Approval of the subscription agreement for new shares and pre-funded warrants issued by the Company signed on October 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
7. Approval of the transfer of know-how and communication agreement signed on December 11, 2024 between the Company and its Deputy Chief Executive Officer, in accordance with Articles L.225-38 et seq. of the French Commercial Code;
8. Approval of the subscription agreement for new shares issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
9. Approval of the subscription agreement for pre-funded warrants issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
10. Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2024 (from December 13, 2024);
11. Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer until December 13, 2024 and as Chief Executive Officer from December 13, 2024 for the financial year ended December 31, 2024;
12. Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31, 2024;
13. Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;